Latest / Family Business Stories with Fexingo: Succession, Legacy, and Multi-Generational Companies / How the Janssen Family Built a Global Pharmaceutical Giant
Transcript
- Lucas: If you've ever taken a prescription for anything serious — pain, psychosis, allergies, gut issues — there's a decent chance the molecule was discovered in a modest lab in a small Belgian town called Beerse. Luna: By a family-run business, naturally. Lucas: The Janssen family. And the company they built, which they sold to Johnson & Johnson in 1961, went on to produce more than 80 drugs invented by one man: Dr. Paul Janssen. The guy was a machine. Luna: Eighty drugs — that's an astonishing number for a single scientist, even a whole team. Did he have a massive lab? Lucas: He started with a handful of chemists. By the 1970s, Janssen Pharmaceutica employed maybe 500 people in R&D, but Paul was the creative force. He personally directed the synthesis of over 5,000 compounds. And he had this almost photographic memory for chemical structures. Luna: So the family business was essentially built around one genius. That's a massive concentration of risk, right? Lucas: Absolutely. And the story is really about how a family managed that risk — first by selling at the right moment, but then by negotiating a deal that kept their autonomy for decades. It's a case study in how to sell without losing what made you special. Luna: Okay, I want the details on the deal. But first — what drugs did Paul Janssen actually discover? Give me a few that changed medicine. Lucas: Probably the most famous one is fentanyl. He synthesised it in 1960. It's fifty to a hundred times more potent than morphine. In surgical settings, it was revolutionary. Of course, today it's also notorious for the opioid crisis. Luna: Right — that's the one that's everywhere in the news. And he also found haloperidol, the antipsychotic, right? Lucas: Exactly. Haloperidol in 1958 was a breakthrough for schizophrenia. Then there's loperamide — Imodium — which millions take for diarrhea. Domperidone for nausea. Levamisole, a dewormer that later had a weird second life as a veterinary drug and a cocaine adulterant. The list goes on. Luna: It's incredible that one person can have that kind of impact. But the family business — how did they get started? This wasn't a centuries-old dynasty like some we've covered. Lucas: No, it's a mid-twentieth-century story. Paul's father, Constant Janssen, was a physician and entrepreneur. He founded a small company in 1934 in Turnhout, Belgium, selling medical products. Paul studied medicine and pharmacology at the University of Ghent, then took over the family business in 1953. Luna: So it was a classic generational handover, but the son was a scientific prodigy. Lucas: Exactly. Paul immediately shifted the company's focus from distributing medical supplies to original drug research. He built a lab in Beerse, a village with no scientific tradition. And within a decade, he'd discovered several major drugs. Luna: But by 1961 they were selling to Johnson & Johnson. Why? They seemed to be on a roll. Lucas: Paul was brilliant at chemistry, but less interested in running a global business. He needed capital for R&D and distribution. Johnson & Johnson offered a deal that looked perfect: they would buy the company, but Janssen would remain fully autonomous in research. Paul would report to nobody on scientific decisions. Luna: That's an unusual arrangement. How did they make it work? Lucas: The deal was structured so that Janssen Pharmaceutica operated as a separate subsidiary. Paul got to keep his Beerse lab exactly as it was. Johnson & Johnson provided the money for expansion, the sales force, and the regulatory muscle. And for decades, it worked brilliantly. Luna: But eventually — as with most acquisitions — the parent company's culture must have started to seep in. Lucas: It did. Paul retired as CEO in 1991, though he stayed active in research until his death in 2003. After he left, Johnson & Johnson slowly integrated Janssen more tightly. The Beerse lab still exists, but it's now part of the J&J global R&D machine. The family name remains on the building, but the family itself is out of operational control. Luna: So the autonomy lasted about thirty years. That's a pretty good run for a post-acquisition arrangement. Lucas: It's exceptional. Most family businesses that sell lose their identity within five to ten years. The Janssens managed to preserve the culture of a scrappy Belgian lab inside a Fortune 500 company for a generation. The key was the personal relationship between Paul and the Johnson & Johnson leadership at the time. Luna: But that's fragile. If the CEOs change, the deal changes. Lucas: Exactly. And that's what happened. By the late 1990s, J&J was pushing for more integration, standardised processes, shared services. Paul fought it, but he was losing influence. He once said, 'I don't want to become a division of Johnson & Johnson. I want to remain Janssen.' But large corporations are powerful forces. Luna: Let's talk about the numbers. What was the company worth when they sold? Lucas: The acquisition price in 1961 was roughly $60 million in stock. That seems small today, but it was a huge sum then. And the real value was the pipeline. By the 1970s, Janssen Pharmaceutica was contributing over $100 million in annual revenue to J&J — and that was from just a few blockbuster drugs. Luna: And what about the family's wealth? Did Paul become personally rich? Lucas: He became very wealthy on paper, but he famously lived modestly. He drove an old car, wore simple suits. His passion was the lab. He once said, 'The best thing money can buy is the freedom to do research.' He ploughed much of his personal fortune into the foundation that still supports research in Belgium. Luna: So the money went back into science. That's a very different story from some other pharma families we could mention. Lucas: Completely different. The Janssen Foundation funds neuroscience and infectious disease research. It has assets of several hundred million euros. That's the family's legacy — not a luxury brand or a sports team, but a research engine. Luna: There's also the controversy around fentanyl. Paul Janssen's invention is at the centre of the opioid crisis. How does the family handle that legacy? Lucas: It's complicated. Paul died in 2003, before the crisis really escalated. He always defended fentanyl as a safe surgical anaesthetic when used properly. The abuse came from illicit versions, not the original pharmaceutical product. But as the opioid epidemic grew, the Janssen name became tangled in litigation. Johnson & Johnson, which now owns the drug, has faced billions in lawsuits. Luna: So the family itself isn't being sued, but the brand is stained. Lucas: Right. The family foundation doesn't mention fentanyl. They focus on the other drugs and the scientific method. It's a selective memory, but also a genuine reflection of what Paul cared about. He was a scientist, not a marketer. Luna: Let me ask you a question that bears on other family businesses: could Janssen have stayed independent? What if they hadn't sold? Lucas: They probably couldn't have scaled globally. Belgium is a small market. To get drugs approved in the US and Japan, you need vast regulatory and sales infrastructure. Johnson & Johnson provided that. Without the deal, many of Paul's drugs might have remained only in Europe. Luna: So the sale was necessary for impact, but it cost them control. Lucas: Exactly. And that's the central tension of this story. The family chose global impact over family control. It's a trade-off more family businesses face than they admit. Luna: I want to hear about the culture in that Beerse lab. What made it special? Lucas: Paul ran it like an academic institute, not a corporate lab. There were no rigid hierarchies. Chemists and biologists shared offices. Friday afternoons were free for blue-sky experiments. He encouraged failure — if you didn't fail, you weren't trying enough. And he personally read every lab notebook. Luna: That's intense. A CEO reading lab notebooks? Lucas: He was a working scientist until his last days. In the 1990s, when he was in his 70s, he would still walk through the labs at 7:00 AM, asking about results. He could recall a compound's activity from twenty years earlier. People worshipped him. Luna: But that kind of cult of personality can also be a weakness. What happened after he died? Lucas: The lab's output declined. Without Paul's instinct and memory, the hit rate dropped. J&J shifted more resources to other R&D sites. Today, Beerse is one of several J&J research hubs, and the Janssen family has no operational role. The name lives on, but the family business is effectively over. Luna: Speaking of the name living on — it's interesting that J&J retained the Janssen brand. That's rare in pharma acquisitions. Lucas: It is. J&J has a number of subsidiaries that kept their original names: Janssen, Ethicon, DePuy. The company learned that acquiring with a light touch preserves value. But that policy only works if the acquired company continues to outperform. Once performance slips, integration accelerates. Luna: That's a lesson for any family considering a sale. If you want to preserve your identity, you need to keep outperforming. Lucas: Exactly. And that's hard to sustain over generations, especially when your competitive advantage was a once-in-a-generation genius. Luna: You know, these deep dives into family business history are exactly the kind of thing that makes me think differently about my own work. I'm sure listeners feel the same. Lucas: I hope so. If these conversations have moved your work forward in some small way, consider tossing a couple of dollars a month to keep them going. Buy me a coffee dot com slash fexingo — it genuinely keeps the show ad-free and me digging up stories like this one. Luna: Yeah, it's simple and it makes a real difference. We don't have sponsors, so listener support is what keeps us going. Lucas: Right. So back to the Janssens: one final thing I want to leave you with. Paul Janssen once said, 'The only way to discover drugs is to have good ideas and to test them.' That sounds simple, but the family business structure — autonomous, patient, long-term — gave him the freedom to do exactly that. Luna: And the sale gave him the resources. The lesson might be: know what you're good at, and find partners who protect that. Lucas: Exactly. The Janssen story shows you can sell and still keep your soul — if you negotiate the right terms, and if the buyer respects them. But it also shows that even the best deal eventually fades. That's the bittersweet truth about family business exits. Luna: A good reminder for any family thinking about the future. Lucas: Absolutely. And with that, I think we've covered the Janssens.